All In Biotech

Free tool

FAERS Monitor: Varibar Honey

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208143 or its brand name (Varibar Honey, Barium Sulfate). Reports on generic versions are filed under their own applications.

Reports

353

Serious

212

60% of reports

Hospitalization

123

Death reported

31

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • urticaria27
  • diarrhoea26
  • pruritus19
  • acute kidney injury18
  • dyspnoea18
  • renal failure18
  • no adverse event16
  • vomiting16
  • chronic kidney disease15
  • rash15
  • abdominal pain13
  • nausea13
  • drug hypersensitivity12
  • fatigue12
  • aspiration11

Reports by year received

View as table
YearReports
20052
20063
20073
200821
20096
201010
201113
201212
201317
201413
20159
201620
201728
201827
201927
202018
202127
202232
202323
202412
202517
202613

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,806 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
aspirationSignal1159.933.5579
chronic kidney diseaseSignal1511.87.2138
urticariaSignal279.66.7201
renal failureSignal188.15.1105
acute kidney injurySignal187.04.587
no adverse eventSignal165.33.351
drug hypersensitivitySignal123.72.121
abdominal painSignal133.32.019
pruritusSignal192.91.923
diarrhoeaSignal262.41.720
rashSignal152.11.27
vomitingSignal162.01.38
dyspnoea181.91.27
nausea131.00.60
fatigue120.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.